Evitalife Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 2.00 M
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 M
- Revenue Growth 141.56%
- Profit Growth 135.11%
- Ebitda 134.44%
- Net Worth 144.57%
- Total Assets 209.53%
About Evitalife Pharma
Evitalife Pharma Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 January 2012 and has a history of 13 years and one month. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹2.50 M.
Rohit Barnwal and Subhash Kumar serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24233DL2012PTC229963
- Company No.
229963
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jan 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Pharma
Who are the key members and board of directors at Evitalife Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subhash Kumar  | Director | 13-Mar-2016 | Current |
| Rohit Barnwal | Director | 14-Jan-2012 | Current |
Financial Performance of Evitalife Pharma.
Evitalife Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 141.56% increase. The company also saw a substantial improvement in profitability, with a 135.11% increase in profit. The company's net worth Soared by an impressive increase of 144.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Evitalife Pharma?
In 2021, Evitalife Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Evitalife Science Private Limited
Rohit Barnwal and Subhash Kumar are mutual person
Charges (Loans)
Open Charges
₹2.50 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Aug 2021 | Canara Bank | ₹2.50 M | Open |
How Many Employees Work at Evitalife Pharma?
Unlock and access historical data on people associated with Evitalife Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Evitalife Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Evitalife Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
